What is Elicio Therapeutics, Inc.'s earnings per share (EPS)?

Elicio Therapeutics, Inc. (ELTX) reported diluted earnings per share of $-2.58 for fiscal year 2025. This represents a 39.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Elicio Therapeutics, Inc. Financials

ELTX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Elicio Therapeutics, Inc. (ELTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

Elicio Therapeutics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.93x

For every $1 of reported earnings, Elicio Therapeutics, Inc. generates $0.93 in operating cash flow (-$37.0M OCF vs -$39.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-33.3x

Elicio Therapeutics, Inc. earns $-33.3 in operating income for every $1 of interest expense (-$37.7M vs $1.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$37.5M

YoY+16.0%

Elicio Therapeutics, Inc.'s EBITDA was -$37.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.0% from the prior year.

Net Income

-$39.6M

YoY+23.8%

Elicio Therapeutics, Inc. reported -$39.6M in net income in fiscal year 2025. This represents an increase of 23.8% from the prior year.

EPS (Diluted)

$-2.58

YoY+39.3%

Elicio Therapeutics, Inc. earned $-2.58 per diluted share (EPS) in fiscal year 2025. This represents an increase of 39.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$37.0M

YoY+0.5%

Elicio Therapeutics, Inc. generated -$37.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 0.5% from the prior year.

Cash & Debt

$18.6M

YoY+5.4%

5Y CAGR-11.7%

Elicio Therapeutics, Inc. held $18.6M in cash against $9.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+61.4%

Elicio Therapeutics, Inc. had 18M shares outstanding in fiscal year 2025. This represents an increase of 61.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-2418.8%

Elicio Therapeutics, Inc.'s ROE was -2418.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$24.9M

YoY-26.0%

5Y CAGR-8.6%

Elicio Therapeutics, Inc. invested $24.9M in research and development in fiscal year 2025. This represents a decrease of 26.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$16K

YoY-81.6%

5Y CAGR-17.2%

Elicio Therapeutics, Inc. invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 81.6% from the prior year.

ELTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$2.3M-91.9%	$28.3M+883.1%	$2.9M
Cost of Revenue	N/A	N/A	N/A	$0-100.0%	$433K-63.6%	$1.2M
Gross Profit	N/A	N/A	N/A	$2.3M-91.7%	$27.9M+1549.6%	$1.7M
R&D Expenses	$24.9M-26.0%	$33.7M+41.1%	$23.8M+31.7%	$18.1M-62.8%	$48.7M+24.9%	$39.0M
SG&A Expenses	$12.8M+13.1%	$11.3M-4.8%	$11.9M+111.3%	$5.6M-69.5%	$18.5M+2.8%	$18.0M
Operating Income	-$37.7M+16.2%	-$45.0M-25.9%	-$35.7M-50.6%	-$23.7M+39.6%	-$39.3M+28.9%	-$55.3M
Interest Expense	$1.1M+149.0%	$455K-57.0%	$1.1M-70.6%	$3.6M+294.7%	-$1.8M+79.1%	-$8.8M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$39.6M+23.8%	-$51.9M-47.5%	-$35.2M-24.8%	-$28.2M+48.3%	-$54.6M+31.9%	-$80.1M
EPS (Diluted)	$-2.58+39.3%	$-4.25+38.9%	$-6.96	$-89.27-4525.4%	$-1.93+64.5%	$-5.43

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$5.0M-28.1%	$7.0M-9.9%	$7.8M	N/A	$7.2M-11.9%	$8.2M+8.2%	$7.6M
SG&A Expenses	N/A	$3.0M-2.6%	$3.1M+4.3%	$3.0M	N/A	$3.1M+14.3%	$2.7M+2.3%	$2.7M
Operating Income	N/A	-$8.0M+20.3%	-$10.1M+6.0%	-$10.7M	N/A	-$10.3M+5.3%	-$10.9M-6.7%	-$10.2M
Interest Expense	N/A	$426K+119.6%	$194K+10.2%	$176K	N/A	$137K+179.6%	$49K+36.1%	$36K
Income Tax	N/A	$0	$0	$0	N/A	$0	$0	$0
Net Income	N/A	-$10.1M+4.5%	-$10.6M+5.8%	-$11.2M	N/A	-$18.8M-160.6%	-$7.2M+38.9%	-$11.8M
EPS (Diluted)	N/A	$-0.60+9.1%	$-0.66+24.1%	$-0.87	N/A	$-1.39-117.2%	$-0.64+44.3%	$-1.15

ELTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$25.9M-8.2%	$28.2M+3.8%	$27.1M+19.8%	$22.7M-76.5%	$96.5M+103.8%	$47.3M
Current Assets	$19.3M-6.7%	$20.7M+26.6%	$16.3M+52.5%	$10.7M-88.3%	$91.2M+115.7%	$42.3M
Cash & Equivalents	$18.6M+5.4%	$17.6M+36.6%	$12.9M+109.5%	$6.2M-93.1%	$88.8M+156.5%	$34.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$24.2M-38.7%	$39.5M+150.4%	$15.8M-87.4%	$124.8M-27.0%	$171.0M+24.1%	$137.8M
Current Liabilities	$8.1M-29.6%	$11.5M+18.1%	$9.8M+42.0%	$6.9M-39.2%	$11.3M-89.5%	$107.4M
Long-Term Debt	$9.4M-53.0%	$20.0M	N/A	N/A	$0-100.0%	$635K
Total Equity	$1.6M+114.5%	-$11.3M-199.5%	$11.4M+111.1%	-$102.1M-37.0%	-$74.5M+17.6%	-$90.4M
Retained Earnings	-$233.7M-20.4%	-$194.1M-36.5%	-$142.2M-32.9%	-$107.0M+50.3%	-$215.1M-34.0%	-$160.6M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$25.9M-8.6%	$28.3M-4.2%	$29.5M+4.9%	$28.1M-0.1%	$28.2M-26.6%	$38.4M+143.7%	$15.8M-35.7%	$24.5M
Current Assets	$19.3M-10.0%	$21.5M-5.0%	$22.6M+7.9%	$20.9M+1.2%	$20.7M-32.5%	$30.6M+358.2%	$6.7M-52.7%	$14.1M
Cash & Equivalents	$18.6M-9.9%	$20.6M-6.7%	$22.1M+20.4%	$18.4M+4.2%	$17.6M-32.3%	$26.0M+659.6%	$3.4M-71.1%	$11.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$24.2M-1.0%	$24.5M-11.6%	$27.7M+43.9%	$19.2M-51.3%	$39.5M-31.2%	$57.4M+229.7%	$17.4M-11.3%	$19.6M
Current Liabilities	$8.1M+24.5%	$6.5M-34.3%	$9.9M-13.1%	$11.4M-1.0%	$11.5M+27.7%	$9.0M+18.9%	$7.6M+27.5%	$6.0M
Long-Term Debt	$9.4M-3.2%	$9.7M+4.1%	$9.3M	N/A	$20.0M	N/A	N/A	N/A
Total Equity	$1.6M-57.1%	$3.8M+108.1%	$1.8M-79.4%	$8.9M+178.7%	-$11.3M+40.4%	-$19.0M-1049.3%	-$1.7M-133.9%	$4.9M
Retained Earnings	-$233.7M-3.4%	-$226.0M-4.7%	-$215.9M-5.1%	-$205.3M-5.8%	-$194.1M-7.8%	-$180.1M-11.7%	-$161.3M-4.7%	-$154.0M

ELTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$37.0M+0.3%	-$37.1M-13.4%	-$32.7M-47.4%	-$22.2M+57.9%	-$52.6M-130.0%	-$22.9M
Capital Expenditures	$16K-81.6%	$87K+31.8%	$66K-89.9%	$654K+71.2%	$382K+831.7%	$41K
Free Cash Flow	-$37.0M+0.5%	-$37.2M-13.4%	-$32.8M-43.5%	-$22.8M+56.9%	-$53.0M-131.3%	-$22.9M
Investing Cash Flow	-$16K+81.0%	-$84K-162.5%	-$32K+95.1%	-$654K-71.2%	-$382K-831.7%	-$41K
Financing Cash Flow	$36.7M-13.3%	$42.3M+9.6%	$38.6M+82.1%	$21.2M-80.2%	$107.2M+104.5%	$52.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$150K	$0	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$6.8M+38.7%	-$11.1M-23.9%	-$8.9M+11.6%	-$10.1M-15.7%	-$8.7M-20.2%	-$7.3M+18.5%	-$8.9M+26.3%	-$12.1M
Capital Expenditures	$16K	$0	N/A	N/A	$45K	$0-100.0%	$42K	$0
Free Cash Flow	-$6.8M+38.5%	-$11.1M	N/A	N/A	-$8.8M-20.8%	-$7.3M+18.9%	-$9.0M+26.0%	-$12.1M
Investing Cash Flow	-$16K	$0	$0	$0+100.0%	-$45K	$0+100.0%	-$42K-1500.0%	$3K
Financing Cash Flow	$4.9M-49.2%	$9.6M-19.8%	$11.9M+15.5%	$10.3M+4449.8%	$227K-99.3%	$30.8M+9632.3%	$316K-97.1%	$11.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0	N/A	N/A

ELTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	100.0%+1.5pp	98.5%+39.8pp	58.7%
Operating Margin	N/A	N/A	N/A	-1031.4%-892.6pp	-138.8%+1780.4pp	-1919.2%
Net Margin	N/A	N/A	N/A	-1225.9%-1033.1pp	-192.8%+2588.7pp	-2781.5%
Return on Equity	-2418.8%	N/A	-309.5%	N/A	N/A	N/A
Return on Assets	-153.0%+31.2pp	-184.2%-54.5pp	-129.7%-5.2pp	-124.5%-67.9pp	-56.5%+112.7pp	-169.2%
Current Ratio	2.38+0.6	1.80+0.1	1.68+0.1	1.56-6.5	8.08+7.7	0.39
Debt-to-Equity	5.75+7.5	-1.77-3.2	1.39+2.6	-1.22-1.2	0.000.0	-0.01
FCF Margin	N/A	N/A	N/A	-992.3%-805.0pp	-187.3%+608.9pp	-796.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-264.2%+311.6pp	-575.9%-450.0pp	-125.9%	N/A	N/A	N/A	-242.9%
Return on Assets	N/A	-35.6%+0.1pp	-35.8%+4.1pp	-39.8%	N/A	-49.1%-3.2pp	-45.9%+2.4pp	-48.3%
Current Ratio	2.38-0.9	3.29+1.0	2.28+0.4	1.83+0.0	1.80-1.6	3.40+2.5	0.88-1.5	2.37
Debt-to-Equity	5.75+3.2	2.55-2.5	5.09+2.9	2.16+3.9	-1.77+1.3	-3.02+7.5	-10.53-14.6	4.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

NeOnc Technologies Holdings Inc NTHI

$141.6M

Sellas Life Sciences Group Inc SLS

$741.7M

C4 Therapeutics, Inc. CCCC

$275.2M

Innate Pharma Sa IPHA

$128.4M

Kyverna Therapeutics KYTX

$536.2M

Frequently Asked Questions

Is Elicio Therapeutics, Inc. profitable?

No, Elicio Therapeutics, Inc. (ELTX) reported a net income of -$39.6M in fiscal year 2025.

What is Elicio Therapeutics, Inc.'s EBITDA?

Elicio Therapeutics, Inc. (ELTX) had EBITDA of -$37.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Elicio Therapeutics, Inc. have?

As of fiscal year 2025, Elicio Therapeutics, Inc. (ELTX) had $18.6M in cash and equivalents against $9.4M in long-term debt.

What is Elicio Therapeutics, Inc.'s return on equity (ROE)?

Elicio Therapeutics, Inc. (ELTX) has a return on equity of -2418.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Elicio Therapeutics, Inc.'s free cash flow?

Elicio Therapeutics, Inc. (ELTX) generated -$37.0M in free cash flow during fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Elicio Therapeutics, Inc.'s operating cash flow?

Elicio Therapeutics, Inc. (ELTX) generated -$37.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Elicio Therapeutics, Inc.'s total assets?

Elicio Therapeutics, Inc. (ELTX) had $25.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Elicio Therapeutics, Inc.'s capital expenditures?

Elicio Therapeutics, Inc. (ELTX) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Elicio Therapeutics, Inc. spend on research and development?

Elicio Therapeutics, Inc. (ELTX) invested $24.9M in research and development during fiscal year 2025.

How many shares does Elicio Therapeutics, Inc. have outstanding?

Elicio Therapeutics, Inc. (ELTX) had 18M shares outstanding as of fiscal year 2025.

What is Elicio Therapeutics, Inc.'s current ratio?

Elicio Therapeutics, Inc. (ELTX) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.

What is Elicio Therapeutics, Inc.'s debt-to-equity ratio?

Elicio Therapeutics, Inc. (ELTX) had a debt-to-equity ratio of 5.75 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Elicio Therapeutics, Inc.'s return on assets (ROA)?

Elicio Therapeutics, Inc. (ELTX) had a return on assets of -153.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Elicio Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Elicio Therapeutics, Inc. (ELTX) had $18.6M in cash against an annual operating cash burn of $37.0M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Elicio Therapeutics, Inc.'s Piotroski F-Score?

Elicio Therapeutics, Inc. (ELTX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Elicio Therapeutics, Inc.'s earnings high quality?

Elicio Therapeutics, Inc. (ELTX) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Elicio Therapeutics, Inc. cover its interest payments?

Elicio Therapeutics, Inc. (ELTX) has an interest coverage ratio of -33.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.